$BNTX

$90.40▲ +3.3% YTD

9 SEC 13D/G filings tracked · Last updated Nov 3, 2026

Filing History

CP $90.40▲ +3.3%Nov 3, 2026 · ThinkSabio Blog

$BNTX reported Q3 2026 Adj EPS of $2.03, beating the $0.97 estimate by 109.3%. Revenue of $1.5B beat the $1.2B estimate by 26.8%…

News

BNTX ▲ +3.3% - BioNTech SE

CP $90.40▲ +3.3%Nov 3, 2026 · ThinkSabio Blog

$BNTX - BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update…

News

BNTX ▲ +0.4% - BioNTech SE

CP $88.37▲ +0.4%Oct 26, 2026 · ThinkSabio Blog

$BNTX - BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR…

News

BNTX ▼ -1.4% - BioNTech SE

CP $88.40▲ -1.4%Oct 25, 2026 · ThinkSabio Blog

$BNTX - BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Pl…

News

BNTX ▼ -0.7% - BioNTech SE

CP $90.65▲ -0.7%Oct 22, 2026 · ThinkSabio Blog

$BNTX - BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative…

News

BNTX ▲ +0.2% - BioNTech SE

CP $87.86▲ +0.2%Oct 19, 2026 · ThinkSabio Blog

$BNTX - BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026…

News

BNTX ▼ -1.2% - BioNTech SE

CP $94.75▲ -1.2%Oct 13, 2026 · ThinkSabio Blog

$BNTX - BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck…

News

BNTX ▲ +3.4% - BioNTech SE

CP $100.06▲ +3.4%Sep 14, 2026 · ThinkSabio Blog

$BNTX - BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Pr…

News

BNTX ▼ -7.2% - BioNTech SE

CP $103.42▲ -7.2%Aug 28, 2026 · ThinkSabio Blog

$BNTX volatility weakness…